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Motivation
• In the US, there are > 30 million patients with
osteoarthritis (OA), with an economic burden at
$136.8 billion/year.
• OA causes pain, stiffness, reduced mobility,
disability……
• There is NO FDA-approved drugs to cure OA.
• Pain killers eventually lose efficacy.
• Final solution: total joint replacement.
- A major surgery with complications.
- Not recommended to 4 million young patients
• Insufficiency of Current Models in Developing OA
Drugs
Project Description
We will create three-dimensional (3D), 
multi-component, human  cell-derived, 
microphysiological knee joint-on-a-chip 
(microJoint) for drug development.
Chart 1. The microJoint – a 
microphysiological system mimicking the 
knee joint in the human body.
Potential Impact
Current in vitro cell culture and 
laboratory animal models may not be 
able to fully identify the unexpected poor 
treatment outcomes in humans. In our 
recently developed microJoint tissue chip, 
the novel multi-flow design (Chart 1) 
allows the introduction of treatments 
directly to the “synovial fluid”, or through 
other tissues from another medium 
stream. Through the use of patient-
derived cells, this system will allow the 
generation of OA models with specific 
etiology/pathology/genetic backgrounds, 
as well as the simultaneous testing of 
tissue health as a whole. The outcomes 
gathered from studying the OA 
microJoint will be based on the use of the 
whole “joint”, representing human, not 
animal tissue, and incorporate multiple 
disease initiators. This system is also 
capable of simulating the patient-specific 
etiology of OA and predicting drug 
sensitivity, thus representing a robust 
tool to inform clinical trial design and 
implementation.   
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Context 
• Current in vitro models do not fully
encompass the “whole joint disease”
nature of OA; alternatively, animal




• The tissue chip developed here will be
included multiple human cells-derived
joint tissues and connect them in a
physiological manner (Chart 1).
Project Deliverables
• (1) Introduction of our team to Dr.
Hochberg (M 1-2)
• (2) Preparation of the iPSCs and
materials for new MPS-joint (M 1-2).
• (3) Fabrication of MPS-joint platform
with PDMS (without the mechanism of
applying mechanical force (M2-3).
• (4) Preparation of micro-particles for
controlled release (M 1-2)
• (5) Examination of the drug loading
capacity of micro-particles (M 2-3)
• (6) Creation of new MPS-joint in the
PDMS platform (M 4-5)
• (7) Fabrication and assessment of
mechanics-enabled MPS-joint (M 4-8)
• (8) Attending the Military Health
System Research Symposium (MHSRS)
2021 meeting (M 8)
• (9) Creation of OA model in
mechanics-enabled MPS-joint via
mechanical overloading (M 8-9)
• (10) Examination of release profile of
drugs from micro-particles (M 6-9)
• (11) Inviting Dr. Hochberg to the
University of Pittsburgh (M 9)
• (12) Generation of OA mechanics-
enabled MPS-joint for drug testing (M
10-12)
